Pharsight

Trijardy Xr generic

Trijardy Xr is an anti-diabetic drug owned by Boehringer Ingelheim. Formulated with active ingredients such as Empagliflozin, Linagliptin, and Metformin Hydrochloride, Trijardy Xr is available in tablet, extended-release oral dosage forms. The drug was first authorized for market use on 27 January, 2020, and it has a total of 24 drug patents, two of which have already expired.

When will Trijardy Xr generic be available?

The generic version of Trijardy Xr is expected to become available after 11 December, 2034, upon the expiration of the last drug patent. The generic versions hold the promise of affordable alternatives for type 2 diabetes patients, thereby enhancing the accessible healthcare.

Trijardy Xr uses

Trijardy Xr is primarily used in the treatment of type 2 diabetes mellitus. It helps patients with insufficient glycemic control despite therapy with metformin using a composition comprising empagliflozin, linagliptin, and metformin. It proves beneficial in the treatment of type 2 diabetes in patients with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin in combination with linagliptin and metformin.

Trijardy Xr patent expiration

Currently, Trijardy Xr holds 24 drug patents, out of which two have expired. The remaining patents encompass various aspects of the drug's composition and use, contributing to the effectiveness of Trijardy Xr in the treatment of type 2 diabetes. The last of these patents is set to expire on 11 December, 2034, after which Trijardy Xr generic versions can be produced. Below are the details of the patent:

EPO Oppostions filed on Trijardy Xr

Trijardy Xr dosage

Want to ask something?